Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences Inc. (DTIL), a Delaware corporation, filed this Current Report on Form 8-K on June 21, 2022. The filing reports the entry into an underwriting agreement for a public offering of common stock.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed relates to the proposed capital raise:
- Shares Offered: 35,971,224 shares of common stock.
- Offering Price: $1.39 per share.
- Estimated Net Proceeds: Approximately $46.7 million (after underwriting discounts, commissions, and estimated offering expenses).
Material Changes
The material event reported is the execution of an underwriting agreement with Jefferies LLC. This represents a significant dilution event and a planned increase in the company's cash liquidity. The closing of the offering is expected on June 24, 2022, subject to customary conditions.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds from the offering to fund ongoing and planned research and development activities, as well as for working capital and other general corporate purposes. The filing does not provide specific forward-looking financial guidance or updated operational milestones beyond the funding of R&D.
Investor Verification Checklist
- Verify the final closing date of the offering (expected June 24, 2022) and confirm the actual net proceeds received.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Assess the impact of the 35,971,224 new shares on existing shareholder dilution.
- Confirm the company's current cash runway and burn rate to evaluate the sufficiency of the $46.7 million raise for stated R&D goals.